Scholarlink

Background <p>Carbapenem-resistant <i>Klebsiella pneumoniae</i> (CR-KP) and <i>Pseudomonas aeruginosa</i> (CR-PA) present critical therapeutic challenges. Ceftazidime-avibactam (CAZ-AVI) and imipenem-relebactam (IMI-REL) are key treatment options, but optimal susceptibility testing methods and local resistance mechanisms need clarification.</p> Methods <p>A total of 108 CR‑KP and 102 CR‑PA non‑duplicate clinical isolates (June 2025–February 2026) were tested. Susceptibility to CAZ‑AVI and IMI‑REL was determined by broth microdilution (BMD, reference method), gradient diffusion, and Kirby‑Bauer (K‑B) disk diffusion. Essential agreement (EA), categorical agreement (CA), and error rates were calculated. Carbapenemase types were detected by immunochromatography (CARBA5).</p> Results <p>By BMD, CAZ-AVI susceptibility rates were 88.9% for CR-KP and 96.1% for CR-PA; IMI-REL susceptibility rates were 84.3% and 75.5%, respectively. For CAZ-AVI, gradient diffusion showed excellent CA with BMD (99.1% for CR-KP and 94.1% for CR-PA) and EA of 91.7% and 97.1%, respectively. In contrast, gradient diffusion for IMI-REL was suboptimal (CA 94.4% and EA 86.1% for CR-KP, and CA 84.3% and EA 87.3% for CR-PA). K-B disk diffusion performed poorly for IMI-REL (CA 75.0% for CR-KP and 77.5% for CR-PA; minor errors rates were 24.1% and 20.6%, respectively).</p> Conclusion <p>CAZ-AVI and IMI-REL retain potent in vitro activity against contemporary CR-KP and CR-PA isolates. Gradient diffusion is a reliable alternative to BMD for ceftazidime-avibactam, whereas its accuracy is limited for imipenem-relebactam. K-B disk diffusion for IMI-REL is associated with unacceptably high error rates; reference method confirmation is recommended for isolates yielding non-susceptible results by this method.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Performance evaluation of antimicrobial susceptibility testing methods for ceftazidime-avibactam and imipenem-relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月9日

查看全文
  • Xiaobo Xu,
  • Erjie Lu,
  • Lixin Wu

摘要

Background

Carbapenem-resistant Klebsiella pneumoniae (CR-KP) and Pseudomonas aeruginosa (CR-PA) present critical therapeutic challenges. Ceftazidime-avibactam (CAZ-AVI) and imipenem-relebactam (IMI-REL) are key treatment options, but optimal susceptibility testing methods and local resistance mechanisms need clarification.

Methods

A total of 108 CR‑KP and 102 CR‑PA non‑duplicate clinical isolates (June 2025–February 2026) were tested. Susceptibility to CAZ‑AVI and IMI‑REL was determined by broth microdilution (BMD, reference method), gradient diffusion, and Kirby‑Bauer (K‑B) disk diffusion. Essential agreement (EA), categorical agreement (CA), and error rates were calculated. Carbapenemase types were detected by immunochromatography (CARBA5).

Results

By BMD, CAZ-AVI susceptibility rates were 88.9% for CR-KP and 96.1% for CR-PA; IMI-REL susceptibility rates were 84.3% and 75.5%, respectively. For CAZ-AVI, gradient diffusion showed excellent CA with BMD (99.1% for CR-KP and 94.1% for CR-PA) and EA of 91.7% and 97.1%, respectively. In contrast, gradient diffusion for IMI-REL was suboptimal (CA 94.4% and EA 86.1% for CR-KP, and CA 84.3% and EA 87.3% for CR-PA). K-B disk diffusion performed poorly for IMI-REL (CA 75.0% for CR-KP and 77.5% for CR-PA; minor errors rates were 24.1% and 20.6%, respectively).

Conclusion

CAZ-AVI and IMI-REL retain potent in vitro activity against contemporary CR-KP and CR-PA isolates. Gradient diffusion is a reliable alternative to BMD for ceftazidime-avibactam, whereas its accuracy is limited for imipenem-relebactam. K-B disk diffusion for IMI-REL is associated with unacceptably high error rates; reference method confirmation is recommended for isolates yielding non-susceptible results by this method.